ReviewThe Journal of clinical investigation2007
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?
Review in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart.Pflugers Archiv : European journal of physiology · 2021Article
- Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.Molecular neurobiology · 2017Review
- TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.Nucleic acids research · 2017Article
- Structural Dynamics of Human Argonaute2 and Its Interaction with siRNAs Designed to Target Mutant tdp43.Advances in bioinformatics · 2016Article
- UDP-GlcNAc 2-Epimerase/ManNAc Kinase (GNE): A Master Regulator of Sialic Acid Synthesis.Topics in current chemistry · 2015Review
- Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?Neurodegenerative disease management · 2014Article
- Article
- Article
- TNF-α gene knockout in triple negative breast cancer cell line induces apoptosis.International journal of molecular sciences · 2012Article
- RNA interference: A futuristic tool and its therapeutic applications.Saudi journal of biological sciences · 2012Article
- Delivery of small interfering RNA by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers.ACS nano · 2012Article
- Silencing disease genes in the laboratory and the clinic.The Journal of pathology · 2012Review
- Gene therapy in animal models of autosomal dominant retinitis pigmentosa.Molecular vision · 2012Review
- Inhibition of highly pathogenic PRRSV replication in MARC-145 cells by artificial microRNAs.Virology journal · 2011Article
- Screening siRNAs targeting a novel gene (HA117) and the development of a derivative recombinant adenovirus delivery system.Cancer gene therapy · 2011Article
- Personalized cancer approach: using RNA interference technology.World journal of surgery · 2011Review
- Enhanced stability and knockdown efficiency of poly(ethylene glycol)-b-polyphosphoramidate/siRNA micellar nanoparticles by co-condensation with sodium triphosphate.Pharmaceutical research · 2011Article
- Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.The Journal of clinical investigation · 2011Article
- Silencing early viral replication in macrophages and dendritic cells effectively suppresses flavivirus encephalitis.PloS one · 2011Article
- Double-stranded RNA resists condensation.Physical review letters · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
With unprecedented speed, RNA interference (RNAi) has advanced from its basic discovery in lower organisms to becoming a powerful genetic tool and perhaps our single most promising biotherapeutic for a wide array of diseases. Numerous studies document RNAi efficacy in laboratory animals, and the first clinical trials are underway and thus far suggest that RNAi is safe to use in humans. Yet substantial hurdles have also surfaced and must be surmounted before therapeutic RNAi applications can become a standard therapy. Here we review the most critical roadblocks and concerns for clinical RNAi transition, delivery, and safety. We highlight emerging solutions and concurrently discuss novel therapeutic RNAi-based concepts. The current rapid advances create realistic optimism that the establishment of RNAi as a new and potent clinical modality in humans is near.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.